Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its mRNA technology, prominently utilized in the creation of COVID-19 vaccines. The stock witnessed a downward movement today following a mix of financial results and a notable litigation charge.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on May 1, 2026 19:15

• Moderna posted robust Q1 revenue, fueled by strong international sales of COVID-19 vaccines, although it incurred a substantial net loss mainly attributed to a $950 million settlement for a patent dispute.
• Despite surpassing revenue projections and showcasing progress in its pipeline, the market responded negatively to the company's increased net loss and negative gross margins stemming from the litigation charge.
• Observers are closely monitoring Moderna's pipeline advancements, notably the forthcoming FDA verdict on the mRNA-1010 flu vaccine and advanced oncology trials, as these factors impact the stock's premium valuation despite uncertainties regarding profitability.
• Market sentiment towards Moderna appears to be swayed by the company's financial results, legal challenges, and the critical role of its pipeline in determining its future prospects.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook

Moderna (MRNA) reported strong Q1 2026 revenue, exceeding expectations due to international COVID-19 vaccine sales, and reiterated its 2026 revenue growth guidance. Despite improved cost discipline, a significant $0.9 billion litigation charge led to a wider net loss and negative gross margins. The company's future outlook is largely dependent on its pipeline, particularly the mRNA-1010 flu vaccine's upcoming FDA decision and late-stage oncology trials, which currently drive a premium valuation for the stock despite near-term profitability uncertainties.

https://seekingalpha.com/article/4897425-moderna-q1-earnings-revenue-beat-overshadowed-by-litigation-charge-pipeline-drives-outlook

Why Is Moderna Stock Falling Friday? - Moderna (NASDAQ:MRNA)

Moderna's stock fell on Friday despite beating revenue expectations, primarily due to a litigation settlement charge that led to a net loss. The company reported a narrower-than-expected adjusted loss and higher-than-forecast revenue, driven by increased COVID vaccine sales internationally. Moderna reiterated its goal for significant revenue growth into 2026 and highlighted advancements in its pipeline, including a Phase 3 study for an H5 pandemic influenza vaccine candidate.

https://www.benzinga.com/markets/earnings/26/05/52217081/modernas-legal-hit-steals-spotlight-from-strong-sales

Moderna beats revenue expectations with $389M, but litigation dogs earnings

Moderna exceeded revenue expectations in the first quarter with $389 million, despite reporting a significant net loss of $1.3 billion. The loss was primarily due to a $950 million settlement payment to Arbutus for a patent dispute over lipid nanoparticle technology. CEO Stéphane Bancel expressed confidence in the company's return to prosperity, focusing on international sales, regulatory approvals, and new modalities, even as some regulatory setbacks for its flu vaccines have analysts questioning its breakeven timeline.

https://www.biospace.com/business/moderna-beats-revenue-expectations-with-389m-but-litigation-dogs-earnings

Moderna Reports Q1 2026 Results: Full Earnings Call Transcript

Moderna reported Q1 2026 revenue of $400 million, a significant increase year-over-year, largely due to a strategic partnership with the UK government, and reiterated its expectation of up to 10% revenue growth for 2026. Despite a GAAP net loss of $1.3 billion primarily from a litigation settlement, the company maintained a strong balance sheet with $7.5 billion in cash and investments. Key developments include the EU approval of a flu-COVID combo vaccine and the initiation of a Phase 3 trial for Intismiran in non-small cell lung cancer, with a strategic focus on expanding its commercial portfolio and leveraging AI and robotics.

https://www.benzinga.com/insights/news/26/05/52211250/moderna-reports-q1-2026-results-full-earnings-call-transcript

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Moderna reported its first quarter 2026 financial results, with significant revenue growth ($0.4 billion, 80% from international markets) despite a GAAP net loss of $(1.3) billion due to a non-recurring litigation settlement charge. The company reiterated its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. Key business updates include regulatory approvals in Europe for its flu plus COVID combination vaccine (mCOMBRIAX) and the initiation of a Phase 3 study for intismeran autogene in non-small cell lung cancer.

https://investingnews.com/moderna-reports-first-quarter-2026-financial-results-and-provides-business-updates/

Trending Today

MSCI Inc ($MSCI) Stock Forecast: Down 2.0% Today

Chemours Company (The) ($CC) Stock Forecast: Up 5.5% Today

Steel Dynamics Inc. ($STLD) Stock Forecast: Up 5.2% Today

Marvell Technology Group Ltd. ($MRVL) Stock Forecast: Up 5.1% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Down 2.0% Today

S&P Global Inc. ($SPGI) Stock Forecast: Down 2.1% Today

Clear Secure Inc. ($YOU) Stock Forecast: Up 5.0% Today

First Solar Inc. ($FSLR) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.4% Today

Johnson Controls International plc ($JCI) Stock Forecast: Down 0.5% Today

Moderna Inc. Price History

21.03.2026 - MRNA Stock was up 1.7%

• Moderna's upward market trajectory can be linked to a sequence of favorable occurrences and disclosures:
• Approval of a dual flu and COVID-19 vaccine targeted at older adults in the EU, demonstrating the company's ongoing success in broadening its product offerings.
• Disclosure of encouraging data during the AACR 2026 annual meeting, particularly regarding the impressive response rates seen with mRNA-4359 in melanoma patients, underscoring the potential of Moderna's treatment methodologies.
• Participation in forthcoming investor conferences, underscoring Moderna's proactive approach to engaging with shareholders and showcasing advancements in mRNA technology.
• The downturn observed in Boston Scientific's stock might have indirectly influenced Moderna's upward trend, as investors potentially redirected their attention to firms within the healthcare sector with more promising growth opportunities.

29.03.2026 - MRNA Stock was down 5.1%

• Moderna's stock saw a decline after a revision of Q1 earnings estimates by an investment firm, resulting in a consensus full-year estimate in negative territory.
• Despite surpassing Q4 earnings estimates, Moderna experienced a 33.2% drop in revenue compared to the previous year, causing concerns among investors and contributing to the bearish trend.
• The pessimistic outlook on Moderna's earnings, in combination with overall market sentiment, likely triggered a sell-off as investors reassessed their stakes in the company.
• The decline in Moderna's stock price contrasts with positive developments in other biopharmaceutical companies, such as Regeneron and Biogen, which reported strong earnings and strategic acquisitions, respectively, showcasing the competitive nature of the biotech industry.

23.03.2026 - MRNA Stock was down 5.2%

• The decline in Moderna's stock value could be linked to a notable loss in U.S. government funding for its mRNA research. However, the company showed recovery as it began a Phase 3 trial for an mRNA bird flu vaccine.
• Despite the European Commission approving Moderna's COVID-19-influenza combination vaccine, it was not sufficient to counterbalance the impact of the funding loss from the U.S., prompting concerns among investors regarding the company's financial well-being.
• Investor focus on Regeneron Pharmaceuticals, reinforced by Cantor Fitzgerald's "Overweight" rating and strong quarterly EPS results, potentially diverted attention from Moderna, contributing to the downward trend in its stock performance.
• Additionally, the optimistic prospects for Thermo Fisher Scientific, driven by onshoring initiatives, may have attracted investor interest away from Moderna's ongoing challenges, further influencing its stock price.

01.04.2026 - MRNA Stock was down 5.1%

• Moderna posted robust Q1 revenue, fueled by strong international sales of COVID-19 vaccines, although it incurred a substantial net loss mainly attributed to a $950 million settlement for a patent dispute.
• Despite surpassing revenue projections and showcasing progress in its pipeline, the market responded negatively to the company's increased net loss and negative gross margins stemming from the litigation charge.
• Observers are closely monitoring Moderna's pipeline advancements, notably the forthcoming FDA verdict on the mRNA-1010 flu vaccine and advanced oncology trials, as these factors impact the stock's premium valuation despite uncertainties regarding profitability.
• Market sentiment towards Moderna appears to be swayed by the company's financial results, legal challenges, and the critical role of its pipeline in determining its future prospects.

01.04.2026 - MRNA Stock was down 5.2%

• Strong Q1 2026 financial results were reported by Moderna, with significant revenue growth driven by higher international sales of its COVID-19 vaccine. Despite this positive development, the stock witnessed a bearish movement, potentially linked to profit-taking after a period of strong performance.
• The company's GAAP net loss, attributed to a non-recurring litigation settlement charge, may have also contributed to investor concerns despite the revenue beat.
• Moderna's stock price surge in premarket trading and after-market hours suggests that investors initially reacted positively to the earnings report, but the bearish movement during the trading day indicates a shift in sentiment.
• The reaffirmed growth outlook and expansion into new product approvals demonstrate Moderna's commitment to innovation and long-term growth, which could potentially attract investors back to the stock in the future.

28.03.2026 - MRNA Stock was down 5.1%

• Concerns arose among investors regarding Moderna's collaboration with Salesforce to enhance its commercial operations, potentially leading to worries about integration challenges or operational disruptions.
• High expectations following the presentation of promising combination therapies at AACR 2026 may have disappointed investors if they perceived Moderna's current pipeline as less competitive for future cancer treatment developments.
• Speculation surrounding Moderna's upcoming Q1 2026 earnings report, particularly with projected losses per share, might have contributed to a negative investor sentiment prompting the stock's bearish trend.
• Attention on innovative therapies for diabetic retinopathy and Revolution Medicines' forthcoming annual meeting possibly overshadowed Moderna's core business, impacting investor confidence and attributing to the bearish stock movement.

24.03.2026 - MRNA Stock was down 6.6%

• Moderna (MRNA) recently saw a decrease in its stock price, potentially related to the upcoming financial report projecting an expected decrease in EPS and revenue, as well as ongoing financial difficulties and insider selling.
• This downward trend could be influenced by negative profit margins, projected annual losses, and challenges resulting from reductions in U.S. government funding for its bird-flu initiative.
• While the recent approval of mCOMBRIAX in the EU and ongoing Phase 3 trial for a bird-flu vaccine may have provided some positive momentum, concerns about the company's financial performance appear to have overshadowed these advancements in its product pipeline.
• Investors may be exercising caution due to conflicting signals regarding Moderna's financial prospects and the competitive environment within the biotechnology sector, illustrated by expansions in the CMV infection and iPSC-derived NK cells portfolios.

24.03.2026 - MRNA Stock was down 5.6%

• Expectations for Moderna's (MRNA) Q1 2026 earnings are pessimistic, with analysts predicting a loss. Ongoing financial difficulties, negative margins, and insider selling are among the factors contributing to the downward movement.
• While potential positives like EU approval for mCOMBRIAX and a Phase 3 bird-flu vaccine trial could provide a boost, past funding reductions for its bird-flu program in the U.S. are seen as challenges affecting investor confidence.
• The market's general sentiment towards biotech companies may also be influencing the bearish trend. This is exemplified by the contrasting performance of Regeneron Pharmaceuticals, which received a positive rating reassessment amid the sector's fluctuations.

08.03.2026 - MRNA Stock was up 5.5%

• Moderna's surge in the market may be linked to optimistic views on its international COVID-19 vaccine markets, emphasized by analysts. Expectations of substantial gains from deals like the UK's COVID booster program and future post-pandemic market agreements have spurred investor confidence.
• Despite reduced forecasts for its RSV vaccine, the heightened revenue projections for Moderna's COVID-19 vaccines by analysts at the bank have likely instilled faith in the company's growth prospects among investors.
• The upbeat market reception to Moderna's potential expansion in global markets may have overshadowed the reservations raised by the 'Underperform' rating and $31 price target set by analysts. This hints at a disparity between analyst evaluations and market sentiments.

08.03.2026 - MRNA Stock was up 6.7%

• Moderna saw a significant rise in its stock price following an increase in price target to $35 from $30 by RBC Capital Markets, while maintaining a "Sector Perform" rating.
• This optimistic forecast signifies the market's confidence in Moderna's potential growth within the biotech sector.
• Analyst revisions, including the raised price target, indicate sustained interest and positivity towards Moderna's pipeline and future developments.
• The general positive sentiment towards Moderna may also be influenced by the broader optimistic outlook on biotech firms and healthcare technology progress, driving investor enthusiasm towards innovative solutions such as mRNA-based therapies.

30.03.2026 - MRNA Stock was up 5.2%

• Moderna experienced a notable bullish movement recently, potentially due to improved market sentiment after a period of losses. This rebound might signal restored investor faith in the company.
• Anticipation surrounding the upcoming earnings announcement on May 1, 2026, is likely fueling investor interest, leading to heightened purchasing activity and a rise in the stock's value.
• Positive analyses indicating long-term stock strength may be prompting traders to take positions, particularly given specified entry, target, and stop-loss levels for various trading strategies.
• Factors such as the resolution of a patent dispute with Roivant Sciences Ltd. and encouraging Phase 3 outcomes for Batoclimab may also be bolstering Moderna's resilience and growth prospects within the biopharmaceutical field.

15.03.2026 - MRNA Stock was up 7.5%

• Moderna saw strong bullish movement today possibly due to the positive expectations surrounding its upcoming first-quarter 2026 financial results.
• The company's scheduled live conference call and webcast discussing financial results and future plans may have boosted investor confidence.
• Investor interest remains high in the biotech and healthcare sectors, exemplified by Moderna's positive market response in comparison to developments in other companies.
• Moderna's active engagement with investors and market optimism regarding its financial results likely contributed to the bullish movement in its stock price today.